{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(32)"],"submitter":["Li Y"],"pubmed_abstract":["Pharmacological inhibition of the cell cycle regulatory kinase Wee1 represents a promising strategy to eliminate cancer cells. Wee1 inhibitors cooperate with chemotherapeutics, e. g. nucleoside analogues, pushing malignant cells from S phase towards premature mitosis and death. However, considerable toxicities are observed in preclinical and clinical trials. A high proportion of tumor cells can be distinguished from all other cells of a patient's body by inactivating mutations in the tumor suppressor p53. Here we set out to develop an approach for the selective protection of p53-proficient cells against the cytotoxic effects of Wee1 inhibitors. We pretreated such cells with Nutlin-3a, a prototype inhibitor of the p53-antagonist Mdm2. The resulting transient cell cycle arrest effectively in"],"journal":["Oncotarget"],"pagination":["32339-52"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4741697"],"repository":["biostudies-literature"],"pubmed_title":["Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors."],"pmcid":["PMC4741697"],"pubmed_authors":["Saini P","Li Y","Dobbelstein M","Sriraman A"],"additional_accession":[]},"is_claimable":false,"name":"Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.","description":"Pharmacological inhibition of the cell cycle regulatory kinase Wee1 represents a promising strategy to eliminate cancer cells. Wee1 inhibitors cooperate with chemotherapeutics, e. g. nucleoside analogues, pushing malignant cells from S phase towards premature mitosis and death. However, considerable toxicities are observed in preclinical and clinical trials. A high proportion of tumor cells can be distinguished from all other cells of a patient's body by inactivating mutations in the tumor suppressor p53. Here we set out to develop an approach for the selective protection of p53-proficient cells against the cytotoxic effects of Wee1 inhibitors. We pretreated such cells with Nutlin-3a, a prototype inhibitor of the p53-antagonist Mdm2. The resulting transient cell cycle arrest effectively in","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Oct","modification":"2025-04-26T11:23:28.507Z","creation":"2019-03-27T02:08:25Z"},"accession":"S-EPMC4741697","cross_references":{"pubmed":["26431163"],"doi":["10.18632/oncotarget.5891"]}}